Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Exciting novel treatments being developed for MDS

Lionel Ades • 2 Jun 2020
EHA 2020
Myelodysplastic Syndromes Antibodies Checkpoint inhibitors Pembrolizumab Pevonedistat Venetoclax

Lionel Ades, MD, PhD, Avicenne Hospital, Bobigny, France, talks on exciting novel treatments being developed for myelodysplastic syndromes (MDS). Specifically discussed is the combination of hypomethylating agents with new agents such as those inhibiting IDH1 and IDH2 as well as the use of agents such as venetoclax. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Lionel Ades

3:05
High-risk MDS: pevonedistat and azacitidine vs azacitidine alone
Lionel Ades • 2 Jun 2020
0:59
The current challenges facing high-risk MDS treatment
Lionel Ades • 1 Jun 2020

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals